

I hereby certify that this correspondence is being Electronically Transmitted on the date noted below to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 9, 2010

Date of Deposit  
Magdalena O. Cilella, Ph.D.

Name of applicant, assignee or  
Registered Representative

/Magdalena O. Cilella, Reg. No. 56,619/

Signature  
April 9, 2010

Date of Signature

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of:

Pavcnik et al.

Appln. No.: 10/719,415

Examiner: Christopher D.  
Prone

Filed: November 21, 2003

Art Unit: 3738

For: STENT TISSUE GRAFT PROSTHESIS

Confirmation No. 3409

Attorney Docket No: 8627/1318 (PA-5360-RFB)

### INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 CFR §1.56 and §§1.97-1.98, and more particularly in accordance with 37 CFR §1.97(b), Applicants hereby cite the following references:

U.S. PATENT DOCUMENTS		
DOCUMENT NO.	DATE	NAME
5,916,264	06/29/1999	Von Oepen et al.
6,334,868	01/01/2002	Ham

FOREIGN PATENT DOCUMENTS		
DOCUMENT NO.	DATE	COUNTRY
WO97/24081	07/10/1997	PCT
WO 02/089707A1	11/14/2002	PCT
WO 01/82836A2	11/08/2001	PCT

**OTHER ART – NON PATENT LITERATURE DOCUMENTS**

International Preliminary Examination Report for PCT Application No. PCT/US0337365 dated February 25, 2005

International Search Report for PCT Application No. PCT/US0337365 dated February 25, 2005

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 CFR §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary, 37 C.F.R §1.98(a)(3). Applicants respectfully request the Examiner's consideration of the above references and entry thereof into the record of this application.

By submitting this Statement, Applicants are attempting to fully comply with the duty of candor and good faith mandated by 37 CFR §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 CFR §1.56(a).

The Applicants have calculated no fee to be due in connection with the filing of this Information Disclosure Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Information Disclosure Statement to a deposit account, as authorized in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

April 9, 2010  
Date

/Magdalena O. Cilella, Reg. No. 56,619/  
Magdalena O. Cilella, Ph.D.